IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Donald J. KERRISH, et a

Serial No.: 10/665,728

Filed: September 22, 2003

Customer Number: 20277

Confirmation Number: 4677

Group Art Unit: 1623

Examiner: Unknown

COMPOSITION CONTAINING RIBAVIRIN AND USE THEREOF For:

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop OFR Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Attached is a copy of the Filing Receipt received from the U.S. Patent and Trademark Office in the above-referenced application. It is noted that the Inventors' names are incorrect. Attached is a copy of the Declaration and Power of Attorney Document, which evidences the Inventors' names should read: Donald J. KERRISH, John R. BERGERON, Larry L. AUGSBURGER. Please also note that the priority information on the official filing receipt is incorrect. Attached is a copy of the Amendment filed with the Response to Notice to File Missing Parts, which evidences that priority should only be claimed from U.S. Provisional Application No. 60/411,747, filed September 19, 2002. The applicant is also entitled to Small Entity Status. It is requested that a corrected filing receipt be issued.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP

Daniel Bucca, Ph.D.

Registration No. 42,368

600 13th Street, N.W. Washington, DC 20005-3096 (202) 756-8000 DB:tlb Facsimile: (202) 756-8087

Date: June 3, 2004



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.C. Dox 1450 Alexandria, Vingina 22313-1450 www.usplo.gov

APPL NO.

FILING OR 371 (c) DATE

FIL FEE REC'D ART UNIT

ATTY.DOCKET NO

DRAWINGS

TOT CLMS IND CLMS

10/665,728

09/22/2003

1623

61404-018

20

6

MCDERMOTT, WILL & EMERY 600 13th Street, N.W. Washington, DC 20005-3096



CONFIRMATION NO. 4677

FILING RECEIPT

OC000000011497829

Date Mailed: 12/16/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Donald Kerrish, Residence Not Provided; John Bergeron, Residence Not Provided; Larry Augsburger, Residence Not Provided;

Domestic Priority data as claimed by applicant

This application is a CIP of 09/812,024 03/19/2001

us Provisional 601411,747, find 9119/2002

Foreign Applications

If Required, Foreign Filing License Granted: 12/15/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** Small Entity Status 4.48

Title

Composition containing ribavirin and use thereof

Preliminary Class

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



OTPE YOU

Commissioner for Peters Washington, OC 2023

APPLICATION NUMBER FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS

60/411,747

09/19/2002

80 61404-015

CONFIRMATION NO. 9167

McDERMOTT, WILL & EMERY 600 13th Street, N.W. Washington, DC 20005-3096

OCT 1 1 2002

FILING RECEIPT

OC000000008910200

.ACDERMOTT, WILL & EMER

Date Mailed: 10/07/2002

Receipt is acknowledged of this provisional Patent Application. It will not be examined for patentability and will become abandoned not later than twelve months after its filing date. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Donald Kerrish, Cranberry Township, PA;

If Required, Foreign Filing License Granted 10/04/2002

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Sustained release composition containing ribavirin

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING